Neonatal Pig Mesenchymal Stem Cell Composition for Consistent Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing mesenchymal stem cell therapies for clinical applications face challenges such as variability in effectiveness due to donor-dependent factors, safety concerns, and inconsistent quality, which affect treatments for diseases like graft-versus-host disease, cardiovascular disorders, osteoarthritis, hepatic disorders, respiratory diseases, spinal cord injuries, and renal failure.
Innovation Solution
A pharmaceutical composition utilizing neonatal pig-derived mesenchymal stem cells that express high levels of TGF-β1, TGF-β2, VEGF-A, and VEGF-C, promoting angiogenesis and lymphangiogenesis, effectively treating conditions like peripheral artery diseases, cerebral infarction, myocardial infarction, acute lung injury, wounds, and decubitus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If mesenchymal stem cells from adult donors are used, then donor availability is improved, but treatment effectiveness and quality consistency deteriorate due to donor-dependent variability
Solution Approach 1:
The invention changes the key parameter of donor age from adult to neonatal, which fundamentally alters the characteristics of the stem cells. Neonatal pig-derived mesenchymal stem cells exhibit higher proliferation capacity, smaller cell size, and different immunophenotypic characteristics compared to adult donor cells, thereby achieving both availability and consistency
2Reliability
If mesenchymal stem cells with larger size are used, then cell function and differentiation ability are improved, but risk of pulmonary embolism worsens due to larger cell size
Solution Approach 1:
The invention utilizes the parameter of cell size by selecting neonatal pig-derived mesenchymal stem cells which naturally possess smaller cell size compared to adult donor cells. This parameter change reduces the risk of pulmonary embolism while maintaining therapeutic effectiveness through alternative mechanisms such as higher proliferation capacity and immunoregulatory function
3Adaptability or versatility
If mesenchymal stem cells from various sources are used, then treatment versatility is improved, but quality control and safety worsen due to inconsistent donor conditions
Solution Approach 1:
The invention applies homogeneity by standardizing the donor source to neonatal pigs, which provides consistent and predictable stem cell characteristics. This standardized source ensures uniform quality, safety, and therapeutic effectiveness across different treatments, while the inherent versatility of mesenchymal stem cells allows application to multiple disease conditions
Data Source
AI summary
An object of the present invention is to provide a pharmaceutical composition containing mesenchymal stem cells that exhibit excellent therapeutic effects on various diseases, injured parts, wounds and decubitus. The present invention relates to a pharmaceutical composition for treating a non-porcine animal, the pharmaceutical composition includes a neonatal pig-derived mesenchymal stem cell which produces at least one humoral factor selected from TGF-β1, TGF-β2, VEGF-A and VEGF-C.